Julye Eaton, PA
Physician Assistant · Oklahoma City, OKNPI 1679683221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 565 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,548, 2.8 times the $914 reported in 2021. Among physician assistant clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$988
- Alkermes, Inc.$948
- Johnson & Johnson$850
- AbbVie$786
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$773
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,66396%
- Education$3834%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 97 | $1,704 |
| Otsuka America Pharmaceutical, Inc. | 72 | $988 |
| Alkermes, Inc. | 55 | $948 |
| Johnson & Johnson | 59 | $850 |
| AbbVie | 56 | $786 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $773 |
| Vanda Pharmaceuticals Inc. | 27 | $419 |
| Corium, LLC | 18 | $332 |
| Lundbeck LLC | 18 | $321 |
| Supernus Pharmaceuticals, Inc. | 11 | $282 |
| Sunovion Pharmaceuticals Inc. | 13 | $224 |
| Neurocrine Biosciences, Inc. | 12 | $217 |
| Axsome Therapeutics, Inc. | 15 | $214 |
| Indivior Inc. | 11 | $171 |
| Merck | 10 | $153 |
| Ironshore Pharmaceuticals Inc. | 8 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Noven Therapeutics, LLC | 8 | $123 |
| Tris Pharma Inc | 4 | $76 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Brainsway USA Inc | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,046 in reported general payments places this provider in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $114,372 |
| UzedyRisperidone | 18 | $59,075 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,578 |
| Chlorpromazine Hcl | 19 | $4,380 |
| Lurasidone Hcl | 18 | $3,903 |
| Buspirone Hcl | 81 | $2,376 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 42 | $1,966 |
| Bupropion XlBupropion Hcl | 51 | $1,814 |
| Duloxetine Hcl | 41 | $1,725 |
| Lamotrigine | 72 | $1,445 |
| Aripiprazole | 40 | $1,439 |
| Fluvoxamine Maleate | 24 | $1,411 |
| Trazodone Hcl | 92 | $1,064 |
| Gabapentin | 36 | $1,037 |
| Escitalopram Oxalate | 37 | $948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $217 | $114,37214 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $1,704 | $59,07518 claims |
| Johnson & JohnsonInvega Sustenna | $850 | $29,57813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Oklahoma City
- Jennifer SmithOklahoma City$134K
- Sarah HawkOklahoma City$23K
- Brooke CromerOklahoma City$14K
- Mary Jane RorickOklahoma City$14K
- Alma HintzeOklahoma City$14K
- Emily McLainOklahoma City$13K
- Deniz AktasOklahoma City$13K
- Jovonne SmithOklahoma City$12K
- Anthony SharpOklahoma City$11K
- Whitney PriceOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.